Keros Therapeutics

Dozens of public biopharmaceutical companies have announced plans in 2025 to assess strategic alternatives after clinical trial setbacks or as cash stockpiles dwindled. Both ESSA Pharma and Elevation

Merck & Co. is stopping its second Phase III trial of its pulmonary arterial hypertension drug Winrevair (sotatercept) in as many months due to confidence in the drug, this time in an earlier sett

Keros Therapeutics’ ambitions to go up against Merck & Co’s Winrevair with its investigational pulmonary arterial hypertension therapy, cibotercept, have taken a knock after safety concerns halted

Keros Therapeutics has secured Takeda as a partner for one of its two mid-stage drug candidates, allowing the company to extend its cash runway and focus R&D investment on the other. The companies